Actively Recruiting
Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery
Led by West China Hospital · Updated on 2020-03-20
250
Participants Needed
1
Research Sites
559 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
It has been reported that radiation therapy followed by PCV chemotherapy (procarbazine, lomustine and vincristine) could improve progression-free survival (PFS) and overall survival (OS) in patients with high-risk WHO grade 2 gliomas after surgery. However, procarbazine is not available in China. In clinical practice, Chinese doctors often use radiotherapy combined with temozolomide to treat these patients, though large-scale prospective studies are lacking. This trial aims to confirm whether RT combined with temozolomide can improve PFS and OS in patients with high-risk low-grade gliomas.
CONDITIONS
Official Title
Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed supratentorial WHO grade II gliomas
- Aged 18 to 39 years without total resection, or aged 40 to 70 years with any extent of resection or biopsy
- Karnofsky performance score (KPS) 60
- No more than moderate neurologic symptoms and signs
- Interval between surgery and randomization is less than 12 weeks
- Have signed the consent form
You will not qualify if you...
- WHO grade I gliomas or high-grade gliomas according to WHO's grading system
- Prior radiation therapy to the head and neck region
- Prior chemotherapy
- Synchronous multiple primary malignant tumors excluding carcinoma of the cervix in situ or nonmelanomatous skin cancer
- Prior malignancy's disease-free survival less than 5 years
- Active infection
- Pregnant or breast-feeding patients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xingchen Peng
Chengdu, Sichuan, China, 610041
Actively Recruiting
Research Team
X
Xingchen Peng, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here